SNN

ACCE-researched
Smith & Nephew SNATS Inc. Common Stock
Healthcare · Medical Devices · NYSE · United States
$27.56-0.79%
Market cap $11.5BNext earnings 2026-08-04Updated Sep 19, 2026
FAIR VALUE · CONSENSUS
$27.56+0.0%
confidence-weighted across 5 of 6 models
Now $27.56
$27.56
$14.21$52.45
HoldBronze42
Price vs fair value
9.4% above
-8.6% to fair value
ACCE score
50
out of 100
Analysts
50% buy
4 covering
P/E
18.7x
forward 11.2x
1-year return
-25.6%
Dividend yield
2.88%
Unlock the ACCE read
INVESTOR

Overview

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

-24.5% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Mixed50% buy · 4 covering analysts
● Strong buy 1● Buy 1● Hold 2● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 67% of peers
low 0.0x18.7xhigh 78.0x
ROEbetter than 83% of peers
low -9%12%high 26%
Div yieldbetter than 83% of peers
low 0.0%2.9%high 3.8%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
SN.LSmith & Nephew plc$11.5B18.711.8%0.593.8%-Compare
PENPenumbra Inc. Common Stock$12.5B78.011.4%0.010.0%-Compare
BIOBio-Rad Laboratories Inc. Class A Common Stock$10.1B45.83.1%0.160.0%-Compare
TXG10x Genomics Inc. Class A Common Stock$10.0B--9.4%0.010.0%-Compare
GMEDGlobus Medical Inc. Class A Common Stock$9.9B18.911.8%0.000.0%-Compare
PODDInsulet Corporation Common Stock$9.8B26.426.0%0.630.0%-Compare

Sector report card

Where SNN ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+0.2%
1 month
-6.0%
3 months
-8.4%
6 months
-13.7%
YTD
-16.0%
1 year
-25.6%

SEC filings

40 filings
September 2026
Sep 18
6-KForeign current reportPeriod 2026-09-18
Sep 18
6-KForeign current reportPeriod 2026-09-18
Sep 16
6-KForeign current reportPeriod 2026-09-16
37 more filings + AI summaries on Investor+.INVESTOR